Tango Cash Conversion Cycle vs Free Cash Flow Analysis

TNGX Stock

USD 3.13 0.04 1.29%

Tango Therapeutics financial indicator trend analysis is much more than just breaking down Tango Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Tango Therapeutics is a good investment. Please check the relationship between Tango Therapeutics Cash Conversion Cycle and its Free Cash Flow accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tango Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

For more information on how to buy Tango Stock please use our How to Invest in Tango Therapeutics guide.

Cash Conversion Cycle vs Free Cash Flow

Cash Conversion Cycle vs Free Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Tango Therapeutics Cash Conversion Cycle account and Free Cash Flow. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Tango Therapeutics' Cash Conversion Cycle and Free Cash Flow is -0.03. Overlapping area represents the amount of variation of Cash Conversion Cycle that can explain the historical movement of Free Cash Flow in the same time period over historical financial statements of Tango Therapeutics, assuming nothing else is changed. The correlation between historical values of Tango Therapeutics' Cash Conversion Cycle and Free Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash Conversion Cycle of Tango Therapeutics are associated (or correlated) with its Free Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow has no effect on the direction of Cash Conversion Cycle i.e., Tango Therapeutics' Cash Conversion Cycle and Free Cash Flow go up and down completely randomly.

Correlation Coefficient

-0.03

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Cash Conversion Cycle

Free Cash Flow

The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Most indicators from Tango Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Tango Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tango Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

For more information on how to buy Tango Stock please use our How to Invest in Tango Therapeutics guide.Enterprise Value is likely to rise to about 858.8 M in 2025, whereas Selling General Administrative is likely to drop slightly above 22.1 M in 2025.

	2022	2023	2024	2025 (projected)
Total Operating Expenses	135.9M	150.7M	173.3M	98.9M
Cost Of Revenue	4.0M	115.2M	132.5M	139.1M

Total Operating Expenses Cost Of Revenue

Tango Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Current Deferred Revenue
Total Assets		0.7	-0.84	0.94	0.99	0.94	0.95	0.72	-0.58	-0.88	0.96	0.89	0.71	-0.12	0.03	1.0	0.95	1.0	0.92	0.86	0.97	0.93	1.0	0.98	-0.78	-0.8
Short Long Term Debt Total	0.7		-0.47	0.83	0.66	0.66	0.73	0.92	0.12	-0.92	0.75	0.38	0.92	0.45	-0.14	0.64	0.84	0.69	0.67	0.87	0.79	0.7	0.65	0.78	-0.33	-0.71
Other Current Liab	-0.84	-0.47		-0.82	-0.76	-0.93	-0.68	-0.41	0.55	0.68	-0.79	-0.74	-0.4	0.54	-0.52	-0.86	-0.73	-0.87	-0.95	-0.52	-0.75	-0.93	-0.86	-0.78	0.74	0.65
Total Current Liabilities	0.94	0.83	-0.82		0.88	0.95	0.84	0.84	-0.28	-0.91	0.97	0.68	0.84	0.04	0.16	0.91	0.96	0.95	0.95	0.91	0.93	0.97	0.91	0.94	-0.58	-0.7
Total Stockholder Equity	0.99	0.66	-0.76	0.88		0.87	0.97	0.69	-0.64	-0.86	0.93	0.93	0.69	-0.07	-0.12	0.98	0.93	0.97	0.85	0.86	0.97	0.86	0.98	0.97	-0.81	-0.82
Other Liab	0.94	0.66	-0.93	0.95	0.87		0.79	0.69	-0.44	-0.84	0.91	0.75	0.68	-0.24	0.35	0.93	0.91	0.96	0.99	0.76	0.91	0.99	0.93	0.93	-0.65	-0.71
Net Tangible Assets	0.95	0.73	-0.68	0.84	0.97	0.79		0.69	-0.58	-0.88	0.9	0.9	0.69	0.02	-0.25	0.94	0.9	0.93	0.78	0.86	0.93	0.8	0.94	0.93	-0.83	-0.86
Property Plant And Equipment Net	0.72	0.92	-0.41	0.84	0.69	0.69	0.69		0.11	-0.89	0.77	0.37	1.0	0.54	-0.15	0.65	0.89	0.7	0.66	0.94	0.83	0.7	0.66	0.82	-0.2	-0.58
Net Debt	-0.58	0.12	0.55	-0.28	-0.64	-0.44	-0.58	0.11		0.2	-0.44	-0.87	0.11	0.62	0.05	-0.64	-0.33	-0.57	-0.42	-0.19	-0.44	-0.4	-0.64	-0.45	0.85	0.43
Retained Earnings	-0.88	-0.92	0.68	-0.91	-0.86	-0.84	-0.88	-0.89	0.2		-0.87	-0.65	-0.88	-0.18	0.06	-0.85	-0.96	-0.88	-0.82	-0.9	-0.94	-0.84	-0.85	-0.94	0.55	0.84
Accounts Payable	0.96	0.75	-0.79	0.97	0.93	0.91	0.9	0.77	-0.44	-0.87		0.78	0.77	0.0	0.05	0.95	0.93	0.97	0.93	0.91	0.93	0.94	0.95	0.93	-0.68	-0.66
Cash	0.89	0.38	-0.74	0.68	0.93	0.75	0.9	0.37	-0.87	-0.65	0.78		0.37	-0.35	-0.11	0.92	0.73	0.88	0.73	0.61	0.81	0.72	0.92	0.81	-0.94	-0.76
Non Current Assets Total	0.71	0.92	-0.4	0.84	0.69	0.68	0.69	1.0	0.11	-0.88	0.77	0.37		0.54	-0.14	0.65	0.89	0.7	0.66	0.94	0.83	0.7	0.65	0.81	-0.19	-0.58
Non Currrent Assets Other	-0.12	0.45	0.54	0.04	-0.07	-0.24	0.02	0.54	0.62	-0.18	0.0	-0.35	0.54		-0.62	-0.19	0.13	-0.15	-0.25	0.39	0.06	-0.2	-0.19	0.02	0.48	0.08
Other Assets	0.03	-0.14	-0.52	0.16	-0.12	0.35	-0.25	-0.15	0.05	0.06	0.05	-0.11	-0.14	-0.62		0.05	-0.02	0.09	0.38	-0.22	-0.05	0.34	0.05	-0.01	0.06	0.15
Cash And Short Term Investments	1.0	0.64	-0.86	0.91	0.98	0.93	0.94	0.65	-0.64	-0.85	0.95	0.92	0.65	-0.19	0.05		0.92	1.0	0.92	0.82	0.95	0.93	1.0	0.96	-0.83	-0.79
Common Stock Shares Outstanding	0.95	0.84	-0.73	0.96	0.93	0.91	0.9	0.89	-0.33	-0.96	0.93	0.73	0.89	0.13	-0.02	0.92		0.94	0.88	0.94	0.99	0.9	0.92	0.99	-0.59	-0.79
Short Term Investments	1.0	0.69	-0.87	0.95	0.97	0.96	0.93	0.7	-0.57	-0.88	0.97	0.88	0.7	-0.15	0.09	1.0	0.94		0.95	0.85	0.96	0.95	1.0	0.97	-0.78	-0.78
Non Current Liabilities Total	0.92	0.67	-0.95	0.95	0.85	0.99	0.78	0.66	-0.42	-0.82	0.93	0.73	0.66	-0.25	0.38	0.92	0.88	0.95		0.75	0.87	1.0	0.92	0.89	-0.66	-0.66
Other Current Assets	0.86	0.87	-0.52	0.91	0.86	0.76	0.86	0.94	-0.19	-0.9	0.91	0.61	0.94	0.39	-0.22	0.82	0.94	0.85	0.75		0.91	0.79	0.82	0.9	-0.45	-0.64
Other Stockholder Equity	0.97	0.79	-0.75	0.93	0.97	0.91	0.93	0.83	-0.44	-0.94	0.93	0.81	0.83	0.06	-0.05	0.95	0.99	0.96	0.87	0.91		0.89	0.95	1.0	-0.67	-0.83
Total Liab	0.93	0.7	-0.93	0.97	0.86	0.99	0.8	0.7	-0.4	-0.84	0.94	0.72	0.7	-0.2	0.34	0.93	0.9	0.95	1.0	0.79	0.89		0.93	0.91	-0.65	-0.67
Total Current Assets	1.0	0.65	-0.86	0.91	0.98	0.93	0.94	0.66	-0.64	-0.85	0.95	0.92	0.65	-0.19	0.05	1.0	0.92	1.0	0.92	0.82	0.95	0.93		0.96	-0.82	-0.79
Common Stock	0.98	0.78	-0.78	0.94	0.97	0.93	0.93	0.82	-0.45	-0.94	0.93	0.81	0.81	0.02	-0.01	0.96	0.99	0.97	0.89	0.9	1.0	0.91	0.96		-0.68	-0.83
Property Plant Equipment	-0.78	-0.33	0.74	-0.58	-0.81	-0.65	-0.83	-0.2	0.85	0.55	-0.68	-0.94	-0.19	0.48	0.06	-0.83	-0.59	-0.78	-0.66	-0.45	-0.67	-0.65	-0.82	-0.68		0.77
Current Deferred Revenue	-0.8	-0.71	0.65	-0.7	-0.82	-0.71	-0.86	-0.58	0.43	0.84	-0.66	-0.76	-0.58	0.08	0.15	-0.79	-0.79	-0.78	-0.66	-0.64	-0.83	-0.67	-0.79	-0.83	0.77

Click cells to compare fundamentals

Tango Therapeutics Account Relationship Matchups

Tango Therapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	207.3M	500.2M	436.5M	402.6M	463.0M	352.5M
Other Current Liab	6.1M	8.4M	15.7M	15.4M	13.9M	11.3M
Total Current Liabilities	40.9M	40.7M	55.5M	45.9M	52.8M	46.0M
Total Stockholder Equity	38.6M	344.7M	249.5M	253.1M	291.1M	196.6M
Property Plant And Equipment Net	11.3M	6.1M	57.8M	53.4M	61.4M	30.9M
Net Debt	(20.5M)	(141.2M)	(18.8M)	(27.5M)	(24.7M)	(26.0M)
Retained Earnings	(103.1M)	(161.3M)	(269.5M)	(371.3M)	(334.1M)	(317.4M)
Accounts Payable	1.8M	3.2M	4.5M	2.8M	3.2M	2.9M
Cash	28.4M	142.7M	60.0M	66.4M	76.3M	70.5M
Non Current Assets Total	13.6M	7.8M	61.2M	56.0M	64.4M	33.6M
Non Currrent Assets Other	38K	19K	3.4M	2.6M	3.0M	1.8M
Cash And Short Term Investments	190.3M	485.3M	366.1M	336.9M	387.4M	312.2M
Common Stock Shares Outstanding	31.9M	62.1M	87.8M	94.6M	108.8M	62.8M
Short Term Investments	161.9M	342.5M	306.2M	270.5M	311.1M	241.7M
Liabilities And Stockholders Equity	207.3M	500.2M	436.5M	402.6M	463.0M	352.5M
Non Current Liabilities Total	127.7M	114.7M	131.4M	103.5M	119.0M	109.9M
Other Current Assets	183.5K	5.1M	13.7M	9.7M	11.1M	6.6M
Other Stockholder Equity	141.6M	506.8M	522.6M	624.1M	717.7M	395.6M
Total Liab	168.7M	155.4M	187.0M	149.5M	171.9M	155.8M
Total Current Assets	193.6M	492.3M	375.3M	346.5M	398.5M	318.9M
Accumulated Other Comprehensive Income	17K	(765K)	(3.7M)	186K	167.4K	175.8K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

S	SentinelOne
CRM	Salesforce
MSFT	Microsoft

Additional Tools for Tango Stock Analysis

When running Tango Therapeutics' price analysis, check to measure Tango Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tango Therapeutics is operating at the current time. Most of Tango Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tango Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tango Therapeutics' price. Additionally, you may evaluate how the addition of Tango Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Tango Cash Conversion Cycle vs Free Cash Flow Analysis

Cash Conversion Cycle vs Free Cash Flow

Cash Conversion Cycle vs Free Cash Flow Correlation Analysis

Correlation Coefficient

Cash Conversion Cycle

Free Cash Flow

Tango Therapeutics fundamental ratios Correlations

Tango Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Tango Therapeutics fundamental ratios Accounts

Also Currently Popular

Additional Tools for Tango Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Short Term Investments	+ 1.0	Cash And Short Term Investments
Total Current Assets	+ 1.0	Cash And Short Term Investments

Common Stock Shares Outstanding	- 0.96	Retained Earnings
Non Current Liabilities Total	- 0.95	Other Current Liab
Property Plant Equipment	- 0.94	Cash
Common Stock	- 0.94	Retained Earnings
Other Stockholder Equity	- 0.94	Retained Earnings
Total Liab	- 0.93	Other Current Liab